aTyr Pharma, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ATYR moving today?
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ATYR.
ATYR insider activity
aTyr Pharma, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $955K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | 2026-05-27 | SCHIMMEL PAUL | Insider | buy | $0.50 | 100,000 | 779,143 | $50K | SEC Form 4 |
| 2026-02-04 | 2026-02-04 | Shukla Sanjay | Insider | sell | $0.98 | 3,745 | 153,553 | $4K | SEC Form 4 |
| 2026-02-04 | 2026-02-04 | DENYES NANCY | Insider | sell | $0.98 | 1,118 | 33,124 | $1K | SEC Form 4 |
| 2026-02-04 | 2026-02-04 | Broadfoot Jill Marie | Insider | sell | $0.98 | 1,558 | 37,296 | $2K | SEC Form 4 |
| 2025-10-09 | 2025-10-09 | SCHIMMEL PAUL | Insider | buy | $0.94 | 317,999 | 1,413,023 | $299K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 1 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moATYR contract awards, year to date.
Public federal awards linked to this ticker.
ATYR lobbying filings, year to date.
Registered lobbying filings matched to aTyr Pharma, Inc. Common Stock.